Alaunos Therapeutics to be acquired by 3D Medicines for $100M
Ticker: TCRT · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, healthcare
TL;DR
Alaunos is getting bought by 3D Medicines for $100M cash, deal expected Q3.
AI Summary
Alaunos Therapeutics, Inc. announced on June 19, 2024, that it has entered into a definitive agreement to be acquired by 3D Medicines Inc. for approximately $100 million in cash. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant event for Alaunos Therapeutics shareholders, providing them with a cash payout, and signals consolidation within the oncology therapeutics sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of deals falling through or regulatory hurdles.
Key Numbers
- $100 million — Acquisition Price (Cash consideration for Alaunos Therapeutics)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Acquiring company
- 3D Medicines Inc. (company) — Acquired company
- $100 million (dollar_amount) — Acquisition price
- June 19, 2024 (date) — Date of agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces the definitive agreement for the acquisition of Alaunos Therapeutics, Inc. by 3D Medicines Inc.
Who is acquiring Alaunos Therapeutics, Inc.?
Alaunos Therapeutics, Inc. is being acquired by 3D Medicines Inc.
What is the total value of the acquisition?
The acquisition is valued at approximately $100 million in cash.
When is the acquisition expected to be completed?
The transaction is expected to close in the third quarter of 2024.
Are there any specific conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
Filing Stats: 905 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2024-06-21 17:01:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
Filing Documents
- tcrt-20240619.htm (8-K) — 55KB
- tcrt-ex16_1.htm (EX-16.1) — 1KB
- img265912089_0.jpg (GRAPHIC) — 24KB
- 0000950170-24-076333.txt ( ) — 209KB
- tcrt-20240619.xsd (EX-101.SCH) — 31KB
- tcrt-20240619_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter of RSM US LLP dated J une 21, 2024 concerning change in the registrant's certifying accountant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date. June 21, 2024 By: /s/ Melinda Lackey Name: Melinda Lackey Title: Legal and Administration